CIM
ALXN

CIM Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

CIM Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,260
Closed -$602K – 307
2020
Q3 		$602K Sell
5,260
-5,374
-51% -$580K 0.23% 91
2020
Q2 		$1.19M Hold
10,634
– – 0.48% 30
2020
Q1 		$955K Buy
10,634
+347
+3% +$34.1K 0.47% 35
2019
Q4 		$1.11M Buy
10,287
+6,276
+156% +$671K 0.44% 35
2019
Q3 		$393K Sell
4,011
-459
-10% -$51.7K 0.15% 170
2019
Q2 		$585K Buy
4,470
+246
+6% +$31.7K 0.21% 109
2019
Q1 		$571K Hold
4,224
– – 0.22% 102
2018
Q4 		$411K Sell
4,224
-152
-3% -$18K 0.18% 137
2018
Q3 		$608K Sell
4,376
-3
-0.1% -$376 0.22% 104
2018
Q2 		$544K Sell
4,379
-109
-2% -$12.7K 0.19% 141
2018
Q1 		$500K Sell
4,488
-98
-2% -$11.7K 0.17% 164
2017
Q4 		$548K Sell
4,586
-61
-1% -$7.43K 0.19% 150
2017
Q3 		$652K Sell
4,647
-257
-5% -$34.9K 0.24% 104
2017
Q2 		$597K Sell
4,904
-66
-1% -$7.68K 0.21% 124
2017
Q1 		$603K Sell
4,970
-463
-9% -$59.7K 0.21% 123
2016
Q4 		$665K Buy
5,433
+94
+2% +$11.5K 0.24% 105
2016
Q3 		$654K Sell
5,339
-370
-6% -$47.6K 0.25% 103
2016
Q2 		$667K Sell
5,709
-230
-4% -$32.6K 0.28% 104
2016
Q1 		$827K Sell
5,939
-440
-7% -$64.6K 0.36% 76
2015
Q4 		$1.22M Hold
6,379
– – 0.56% 47
2015
Q3 		$998K Hold
6,379
– – 0.48% 63
2015
Q2 		$1.15M Hold
6,379
– – 0.51% 55
2015
Q1 		$1.1M Hold
6,379
– – 0.48% 65
2014
Q4 		$1.18M Hold
6,379
– – 0.54% 56
2014
Q3 		$1.06M Buy
+6,379
New +$1.05M 0.54% 66
2014
Q1 		– Sell
-7,578
Closed -$1.01M – 218
2013
Q4 		$1.01M Buy
7,578
+810
+12% +$97.2K 0.51% 72
2013
Q3 		$786K Hold
6,768
– – 0.47% 87
2013
Q2 		$624K Buy
+6,768
New +$652K 0.37% 108

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

CIM Investment Management's ALXN Position: Q4 2020 in Review

CIM Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 5,260 shares — an estimated $602K sold.

CIM Investment Management first reported a position in ALXN in Q2 2013 and held it in 28 quarters. The position peaked at $1.22M in Q4 2015. 824 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • CIM Investment Management reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • CIM Investment Management sold 5,260 Alexion Pharmaceuticals shares in Q4 2020, an estimated $602K.
  • CIM Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • CIM Investment Management's Alexion Pharmaceuticals position peaked at $1.22M in Q4 2015.
  • 824 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on CIM Investment Management's 13F filing for Q4 2020, filed 17 Feb 2021.